Welcome to our dedicated page for SEELOS THERAPEUTICS news (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on SEELOS THERAPEUTICS stock.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel therapeutic solutions for central nervous system (CNS) disorders and rare ailments. Based in New York, the company's primary focus is on innovative technologies aimed at treating conditions like major depressive disorder (MDD), post-traumatic stress disorder (PTSD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and more.
Key developments in Seelos' pipeline include:
- SLS-002: An intranasal racemic ketamine targeting acute suicidal ideation and behavior in MDD and PTSD patients. This promising treatment has shown significant efficacy in Phase II trials, with plans for Phase III trials underway.
- SLS-005: A protein stabilizer for treating Sanfilippo syndrome and ALS. Recent trials in collaboration with the HEALEY ALS Platform have highlighted its potential benefits, even though some endpoints were not statistically significant.
- SLS-006: A partial dopamine agonist developed for PD patients, emphasizing symptom relief and improved quality of life.
- Preclinical Programs: These include SLS-007, an anti-alpha-synuclein inhibitor for PD; SLS-008, targeting chronic inflammation in asthma and pediatric orphan indications; and SLS-004 and SLS-010 for PD and narcolepsy, respectively.
Seelos Therapeutics actively engages in various clinical trials and collaborations to advance its therapeutic offerings. The company recently announced public offerings and strategic financial maneuvers to support its robust pipeline, including offerings totaling approximately $10.65 million in gross proceeds. These funds are earmarked for advancing Seelos' clinical programs and general corporate purposes.
Committed to addressing unmet medical needs, Seelos Therapeutics is poised to make significant contributions to the biopharmaceutical landscape, with a keen focus on CNS disorders and rare diseases.
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) released an update letter to stockholders from CEO Raj Mehra, discussing the reverse stock split, underwritten public offering, and the progress of their lead programs SLS-002 and SLS-005. The company is encouraged by the selection of SLS-002 for a U.S. Department of Defense trial and is working closely with the DOD for the study. They also completed an End of Phase II meeting with the FDA for SLS-002 and are working on Phase II/III study in ALS for SLS-005. However, there are concerns about the financial constraints affecting the Phase IIb/III study in Spinocerebellar Ataxia, which was temporarily paused. The company is also seeking approval for proposals related to increasing the number of authorized shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
-
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) closed an underwritten public offering of 1,781,934 shares of common stock, pre-funded warrants to purchase up to 2,422,612 shares of common stock, and accompanying common warrants to purchase up to 4,204,546 shares of common stock. The net proceeds are expected to be approximately $5.0 million, which will be used for general corporate purposes, product development, and to make periodic payments under or repay a portion of outstanding convertible promissory note issued in November 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.03%
Tags
-
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has priced its underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock, and accompanying common warrants to purchase up to 4,204,546 shares of its common stock. The gross proceeds from the offering are anticipated to be approximately $5.55 million, with the net proceeds intended for general corporate purposes, product development, and debt repayment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-47.48%
Tags
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has announced the commencement of an underwritten public offering of shares of its common stock and accompanying common warrants, with the intention to grant the underwriters a 45-day option to purchase additional shares. The offering is subject to market conditions and is being made pursuant to an effective 'shelf' registration statement on Form S-3. The company will use the proceeds from the offering for general corporate purposes and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-47.48%
Tags
-
Rhea-AI Summary
Seelos Therapeutics, Inc. (SEEL) announces that SLS-002 has been selected for an adaptive platform trial to evaluate treatments for post-traumatic stress disorder (PTSD) in active-duty service members and veterans. The trial, funded by the U.S. Department of Defense's Defense Health Agency, will evaluate the safety, tolerability, and efficacy of multiple pharmacotherapeutic interventions. Seelos is optimistic about the potential of SLS-002 to address the significant unmet medical need in treating PTSD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.38%
Tags
-
Rhea-AI Summary
Seelos Therapeutics, Inc. (SEEL) announced a 1-for-30 reverse stock split to regain compliance with the Nasdaq's minimum bid price requirement of $1.00 per share. The reverse stock split will reduce the number of issued and outstanding shares from approximately 167.7 million to approximately 5.6 million, with the new CUSIP number 81577F208.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.53%
Tags
Rhea-AI Summary
Seelos Therapeutics has been selected to present a poster on the study of SLS-005 in a tauopathy model of Alzheimer's disease at the Neuroscience 2023 meeting. The preliminary analysis showed a 46% reduction in tau protein and an 18% reduction in NfL protein biomarker after 6 months of SLS-005 administration. SLS-005 has previously demonstrated an efficacious reduction of mHTT, the mutant protein implicated in Huntington's disease, by 77% in striatum and 84% in cortex.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Seelos Therapeutics has retained Canaccord Genuity to assist in its review of potential partnerships, collaborations, and similar opportunities. The company is focused on developing therapies for central nervous system disorders and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
-
Rhea-AI Summary
Seelos Therapeutics announces encouraging preclinical data for SLS-005, showing a 46% reduction in tau protein and an 18% reduction in NfL biomarker within six months. The company will present these findings at Neuroscience 2023. Top-line data from the SLS-005 Phase II/III trial in ALS is expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
Rhea-AI Summary
Seelos Therapeutics announces securities purchase agreement for 15M shares of common stock and warrants, raising $4.5M
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.71%
Tags
FAQ
What is the current stock price of SEELOS THERAPEUTICS (SEEL)?
The current stock price of SEELOS THERAPEUTICS (SEEL) is $0.39 as of November 18, 2024.
What is the market cap of SEELOS THERAPEUTICS (SEEL)?
The market cap of SEELOS THERAPEUTICS (SEEL) is approximately 527.6K.
What does Seelos Therapeutics, Inc. do?
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders and rare diseases.
What are the key products in Seelos Therapeutics' pipeline?
Key products include SLS-002 for acute suicidal ideation in MDD and PTSD, SLS-005 for ALS and Sanfilippo syndrome, and SLS-006 for Parkinson's disease.
What recent achievements has Seelos Therapeutics made?
Seelos has made significant strides in clinical trials for SLS-002 and SLS-005, and has announced various public offerings to fund ongoing and future projects.
How does SLS-002 work?
SLS-002 is an intranasal racemic ketamine designed to treat acute suicidal ideation and behavior in patients with major depressive disorder and PTSD.
What is the financial status of Seelos Therapeutics?
Seelos has recently raised approximately $10.65 million through public offerings to support its clinical programs and general corporate purposes.
Who are Seelos Therapeutics' key partners?
Seelos collaborates with various institutions, including the Sean M. Healey and AMG Center for ALS research, and engages with financial partners like Titan Partners Group and Roth Capital Partners.
What is SLS-005, and what does it treat?
SLS-005 is a protein stabilizer aimed at treating Sanfilippo syndrome and ALS. It works by stabilizing misfolded proteins and activating autophagy.
What is the status of SLS-005 in clinical trials?
SLS-005 has shown potential benefits in recent trials, particularly in a pre-specified subgroup of ALS patients, although it did not meet all primary and secondary endpoints.
How is Seelos Therapeutics funded?
Seelos is funded through public offerings and private placements, recently raising about $10.65 million to support its development programs and operations.
What are the future plans for Seelos Therapeutics?
Seelos plans to continue advancing its clinical trials, particularly for SLS-002 and SLS-005, and exploring potential partnerships to further its mission of addressing unmet medical needs in CNS disorders and rare diseases.
SEELOS THERAPEUTICS INC
Nasdaq:SEEL
SEEL Rankings
SEEL Stock Data
527.58k
433.82k
0.49%
41.09%
29.41%
Biotechnology
Pharmaceutical Preparations
United States of America
NEW YORK